🔒 Unlock the fastest-moving companies and industries before anyone else.

Fundz gives you access to Companies on the Move and Hot Industries dashboards — updated daily with real-time insights powered by AI.

Join hundreds of teams using Fundz to search and filter through hundreds of thousands of events, including funding, acquisitions, product launches & more — with over 5,000 new signals added weekly.

Plans start at just $19/month. Upgrade now to unlock unlimited search, filters, exports, and exclusive dashboards.

Trusted by sales & BD teams at Oracle, HubSpot, Affinity, and more.

Micreos Secures €32 Million For Its Endolysin-Based Platform As Sustainable Alternative To Antibiotics

09/30/21, 9:30 AM

Location

the hague

Money raised

€32 million

Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

Company Info

Company

Micreos.

Location

the hague, south holland, netherlands

Additional Info

Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications, The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich. Headquartered in The Hague, The Netherlands, Micreos runs its technology center in Zurich, with operations in the Netherlands and the USA. Under the Gladskin brand, Micreos has launched several endolysin-based OTC products for people with inflammatory skin conditions caused or aggravated by S. aureus, including acne, eczema and rosacea, and helped hundreds of thousands of people. SOURCE Micreos

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.